Herpes Zoster (Shingles) Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.
Request for sample @ https://marketreportscenter.com/request-sample/438519
Herpes Zoster (Shingles) pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies. The molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 4, 2, 7 and 2 respectively.
latest report Herpes Zoster (Shingles) – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects.
Check Discount on report @ https://marketreportscenter.com/request-discount/438519
The report is built using data and information sourced from Our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more details of report, table of content, purchase copy of report visit https://marketreportscenter.com/reports/438519/herpes-zoster-shingles-pipeline-review-h2-2016
You can also reach me if you have any questions or need any assistance
Market Reports Center